GPCR

Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously…

<!-- Name:DistributionId Value:8846943 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8787955 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8751212 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8741407 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in…

Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone…

TOKYO, Japan and LONDON and CAMBRIDGE, United Kingdom, July 22, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and…

Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery…

Key focus on enabling prioritization and rapid progression of pipeline programs through to clinical proof-of-concept, a key milestone for value creationSosei Heptares will use the…